Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.



Potential diabetes therapy: Engineered cells that control blood sugar

Cells programmed to sense glucose and release insulin prevent hyperglycemia in diabetic mice

by Michael Torrice
December 12, 2016

Credit: Adapated from Science
To program cells to produce insulin in response to glucose, bioengineers used three proteins. Glucose transporters shuttle the sugar into the cells, where it is metabolized to produce adenosine triphosphate (ATP). Increasing ATP levels shut down potassium ion channels that release potassium ions out of the cell. Stopping this flow changes the voltage across the cell membrane, which in turn activates voltage-gated calcium ion channels. Calcium ions flow into the cell and trigger insulin gene expression.

People with type 1 diabetes must inject themselves with insulin multiple times per day. This is because their immune system has destroyed cells in the pancreas that secrete insulin to maintain a healthy blood glucose level.

A team of bioengineers now report a possible alternative to such injections. The researchers engineered human kidney cells to act like pancreatic β cells, namely to sense blood glucose levels and produce insulin accordingly (Science 2016, DOI: 10.1126/science.aaf4006). When implanted in mice with type 1 diabetes, the cells prevent high blood glucose levels, also known as hyperglycemia.

Right now, “all we offer diabetic patients to cope with their disease is to have them measure their blood glucose levels and then inject a hormone,” says Martin Fussenegger of the Swiss Federal Institute of Technology, Zurich, who led the team that engineered the cells. Although this works, he says, getting the dose right can be tough. “We set out to pioneer a new disease treatment concept.”

Scientists have been working on ways to restore β cells in diabetic patients. For example, doctors have tested therapies in which they transplant islet cells, which contain β cells, into patients. And other researchers have tried to derive β cells from stem cells for transplantation. But all of these potential therapies suffer from the same problem, Fussenegger says: They involve cells the immune system will eventually destroy. “β cells are not very robust cells; that’s why we have diabetes,” he says.

For that reason, Fussenegger and his colleagues decided to program a heartier cell type, the human embryonic kidney (HEK) cell, to behave like delicate β cells. To do so, they replicated the cellular circuitry that allows the pancreatic cells to respond to blood glucose levels.

Basically, β cells regulate glucose levels with the help of three types of proteins that sit in their membranes: glucose transporters, potassium channels, and voltage-gated calcium channels. Glucose enters β cells through the glucose transporters. The cells then metabolize the glucose, producing adenosine triphosphate (ATP). As ATP levels increase, potassium channels shut down, stopping the outward flow of potassium ions from the cell. This changes the voltage across the cell membrane, which in turn activates voltage-gated calcium ion channels. Calcium ions then flow into the cell and turn on gene expression pathways that trigger insulin production.

HEK cells already have a glucose transporter and a potassium channel, so Fussenegger and his colleagues just had to engineer the cells to express the calcium channel and a calcium-dependent gene circuit for insulin production.

To test the resulting cells, the team encapsulated them in alginate beads and implanted them in mice that had their β cells destroyed chemically. The animals survived for the entire three-week experiment, while mice receiving nonengineered cells died after a few days, demonstrating that the β cell mimics could reverse insulin deficiency, which is fatal. The engineered cells also restored normal glucose levels faster than implanted human islet cells.

“Clinicians and people with diabetes will be excited by this new research and by the general notion of engineering glucose-responsive insulin-secreting cells that are not derived from pancreatic islet cells,” says John Pickup, a professor of diabetes and metabolism at King’s College London. Islet-cell-based therapies, he says, have several downsides, including high costs and side effects from the required immune-suppressing medications.

Still, Pickup says this new strategy is in its early stages. For example, the kinetics of the insulin release from the engineered cells needs further tuning to better mimic β cells. The implanted cells, he says, don’t release the hormone fast enough to keep up with the typical blood glucose fluctuations a person experiences throughout the day.

Fussenegger says his team is working on improving the function of the cellular circuit and robustness of the cells.



This article has been sent to the following recipient:

Kathleen lewis (December 14, 2016 5:50 PM)
Promising if it pans out.
Dan Warren (December 15, 2016 2:13 AM)
This is very interesting.
However is there anything being looked at for individuals with type 2 diabetes?
I am very interested in information related to that subject
Michael Torrice (December 18, 2016 7:37 PM)
Hi Dan. Good question. Actually, in this study, the researchers also engineered HEK cells to release glucagon-like peptide 1, which enhances the insulin production of β cells. Such a circuit could provide a therapy for people with type-2 diabetes who still have some β cells remaining.

Leave A Comment

*Required to comment